uploads///Celgene

Celgene on the Street: Analysts Recommendations in January

By

Jan. 25 2018, Updated 7:33 a.m. ET

Celgene’s revenue trends

In 1Q17, 2Q17, and 3Q17, Celgene (CELG) generated revenues of $2.96 billion, $3.27 billion, and $3.29 billion, respectively. On January 18, 2018, Celgene presented its unaudited financial results from 4Q17 and fiscal 2017.

Celgene estimated net sales in 4Q17 of ~$3.48 billion, which represents a 17% rise on YoY (year-over-year) basis. Celgene’s estimated net sales were $13.0 billion for fiscal 2017, which reflects a 16% YoY rise.

In 4Q17, Celgene estimated that its sales of Revlimid, Pomalyst, Otezla, and Abraxane would be $2.19 billion, $442 million, $371 million, and $251 million, respectively, which reflected a ~21% rise, a 17% rise, a 22% rise, and a 6% fall on a YoY basis.

Celgene estimates that its net sales of Revlimid, Pomalyst, Otezla, and Abraxane for fiscal 2017 will be $8.19 billion, $1.6 billion, $1.3 billion and $993 billion, respectively, reflecting 17%, 23%, 26%, and 2% rises on a YoY basis.

Celgene expects to see EPS (earnings per share) of $7.44 for fiscal 2017, which reflects a ~25% growth on a YoY basis. In 4Q17, Celgene anticipates adjusted EPS and an operating margin of $2.00 and 55.3%, respectively, reflecting a ~24% YoY rise and 70-basis-point YoY decline.

The revenue growth of Celgene could boost the share prices of the PowerShares QQQ (QQQ). Celgene makes up about ~1.04% of QQQ’s total portfolio holding.

Article continues below advertisement

Analyst recommendations

So far this January, 31 analysts have been tracking Celgene, and nine of those recommend a “strong buy,” while eight analysts recommend a “buy,” and 13 analysts recommend a “hold.” One analyst recommends “sell” for Celgene in January 2018.

On January 24, 2018, Celgene had consensus 12-month target price of $123.73, which represents an ~18.4% return on investment over the next 12 months.

Peer ratings

Of the 24 analysts tracking Johnson & Johnson (JNJ) in January 2018, ~50% analysts recommend some form of a “buy” for the stock On January 24, 2018, Johnson & Johnson had a consensus 12-month target price of $149.25, which represents a ~5.3% return on investment over the next 12 months.

Of the 23 analysts tracking Merck (MRK) in January 2018, ~61% analysts recommend some form of a “buy” for the stock. On January 24, 2018, Merck had a consensus 12-month target price of $66.86, which represents an 8.4% return on investment over the next 12-months.

Of the 24 analysts tracking Eli Lilly (LLY) this January, ~58% analysts recommend some form of a “buy” for the stock. On January 24, 2018, Eli Lilly had a consensus 12-month target price of $92.09, which represents a 9.1% return on investment over the next 12 months.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.